Clinical Trials Detalhe
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Visão Geral
Gender
ALL
Idade
N/A
Fase
PHASE3
Tipo de Estudo
INTERVENTIONAL
Localização
Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes (Guimarães, Portugal)
Unidade Local De Saude Da Regiao De Leiria Epe (Leiria, Portugal)
Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos (Lisbon, Portugal)
Hosp. Cuf Descobertas (Lisbon, Portugal)
Ulssa Hosp. Santo Antonio (Porto, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT06934226Sumário
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Condições
Plaque Psoriasis
Elegibilidade
Inclusion Criteria: * Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention * Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline * Total psoriasis area and severity index (PASI) \>=12 at screening and baseline * Total investigator global assessment (IGA) \>=3 at screening and baseline * Candidate for phototherapy or systemic treatment for plaque psoriasis Exclusion Criteria: * Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular) * Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients * Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study * Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)